<DOC>
	<DOCNO>NCT00689845</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving rituximab together one five different combination chemotherapy regimens may kill cancer cell . PURPOSE : This clinical trial study give rituximab together combination chemotherapy see well work treat patient primary mediastinal diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Rituximab Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To systematically analyze phenotype molecular characteristic patient primary mediastinal diffuse large B-cell lymphoma . - To determine PET response rate follow chemoimmunotherapy patient . Secondary - To obtain data , nonrandomized basis , regard outcome treatment use different chemoimmunotherapy regimen use omit mediastinal radiotherapy , depend upon practice participate institution . - To analyze progression-free overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive one follow standard chemoimmunotherapy regimen . - Cohort 1 ( R-CHOP-21 ) : Patients receive rituximab IV , cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 oral prednisolone day 1-5 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . - Cohort 2 ( R-CHOP-14 ) : Patients receive rituximab IV , cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 , oral prednisolone day 1-5 , filgrastim ( G-CSF ) subcutaneously ( SC ) day 5-12 . Treatment repeat every 14 day absence disease progression unacceptable toxicity . - Cohort 3 ( R-MACOP-B ) : Patients receive rituximab IV day 1 , 22 , 43 , 64 , 85 , 106 ; cyclophosphamide IV doxorubicin hydrochloride IV day 1 , 15 , 29 , 43 , 57 , 71 ; methotrexate IV day 8 , 36 , 64 ; vincristine IV day 8 , 22 , 36 , 50 ,64 , 78 ; bleomycin IV day 22 , 50 , 78 ; oral prednisolone day 1-84 , follow taper . - Cohort 4 ( R-VACOP-B ) : Patients receive rituximab IV day 1 , 22 , 43 , 64 , 85 , 106 ; cyclophosphamide IV day 1 , 29 , 57 ; doxorubicin hydrochloride IV day 1 , 15 , 29 , 43 , 57 , 71 ; etoposide phosphate IV day 15 , 16 , 43 , 44 , 71 , 72 ; vincristine IV bleomycin IV day 8 , 22 , 36 , 50 , 64 , 78 ; oral prednisolone day 1-84 , follow taper . - Cohort 5 ( R-ACVBP ) : Patients receive rituximab IV , doxorubicin hydrochloride IV , cyclophosphamide IV day 1 ; vindesine IV bleomycin IV day 1 5 ; oral prednisone day 1-5 ; methotrexate intrathecally day 2 ; G-CSF SC day 6-13 4 course absence disease progression unacceptable toxicity . After completion 4 course R-ACVBP , patient receive consolidation therapy comprise high-dose methotrexate IV , rituximab IV , ifosfamide IV , etoposide phosphate IV , cytarabine SC accord protocol GELA LNH03-2B . Patients International Prognostic Index score 4 great disease close proximity spinal cord cerebral meninges may receive prophylactic treatment CNS accord local protocol . Beginning 8 week completion chemoimmunotherapy , patient undergo radiotherapy original tumor volume accord local protocol . Fresh fix tissue prior biopsy obtain possible . Samples analyze CD3 , CD20 , CD30 , CD15 , CD10 , Bcl-6 , Bcl-2 , MAL protein ( available ) , Ki-67 via immunohistochemistry . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary mediastinal diffuse large Bcell lymphoma CD20positive disease Any stage disease Must dominant mass within anterior mediastinum PATIENT CHARACTERISTICS : ANC ≥ 1.5 x 10^9/L ( unless due lymphoma ) Platelets ≥ 100 x 10^9/L ( unless due lymphoma ) WBC ≥ 3.0 x 10^9/L ( unless due lymphoma ) Serum creatinine ≤ 2 time upper limit normal ( ULN ) ( unless due lymphoma ) AST/ALT ≤ 2.5 time ULN ( unless due lymphoma ) Total bilirubin ≤ 2.5 time ULN ( unless due lymphoma ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must fit receive chemotherapy curative intent No evidence clinically significant cardiac disease* within past 12 month , include follow : Symptomatic ventricular arrhythmia Congestive heart failure Myocardial infarction NOTE : * Cardiac compromise due local extension lymphoma exclusion criterion absence cardiac disease . No known HIV infection No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule Able willing give inform consent undergo staging , include PET scan PRIOR CONCURRENT THERAPY : No prior treatment lymphoma Prior corticosteroid 1 week allow relief local compressive symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>